Skip to Content

What are the names of the BTK inhibitors?

What are the names of the approved drugs that inhibit Bruton's tyrosine kinase? What are they used to treat?

Medically reviewed by Drugs.com. Last updated on Nov 24, 2019.

Official Answer

by Drugs.com

The Bruton's tyrosine kinase (BTK) inhibitors include Imbruvica (ibrutinib), Calquence (acalabrutinib), and Brukinsa (zanubrutinib).

Imbruvica (ibrutinib) Capsules and Tablets

FDA Approved: November 13, 2013
Company: Janssen Biotech, Inc.

Treatment for adult patients with:

  • Mantle cell lymphoma (MCL) who have received at least one prior therapy.
    Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL).
  • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion.
  • Waldenström’s macroglobulinemia (WM).
  • Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
    Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

Calquence (acalabrutinib) Capsules

FDA Approved: October 31, 2017
Company: AstraZeneca

Treatment for adult patients with:

  • Mantle cell lymphoma (MCL) who have received at least one prior therapy.
    This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
  • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL).

Brukinsa (zanubrutinib) Capsules

FDA Approved: November 14, 2019
Company: BeiGene, Ltd.

Treatment for adult patients with:

  • Mantle cell lymphoma (MCL) who have received at least one prior therapy.
    This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Related Medical Questions

Drug Information

Related Support Groups